Filter Results
Clinical Studies
Results filtered:Study status:
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
Closed for Enrollment
-
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation (BESTOW)
Rochester, Minn.
This is a randomized, multicenter, open-label, active control study to assess the safety and efficacy of tegoprubart compared with tacrolimus in the preservation of allograft function after kidney transplantation. Approximately 120 de novo kidney transplant recipients will receive rATG (Thymoglobulin®) induction, corticosteroid maintenance, mycophenolate, and will be randomized 1:1 to receive either tegoprubart 20 mg/kg intravenously (IV) every 21 days after an initial loading period or twice daily oral tacrolimus.
-
Development and Validation of a Kidney Transplant-Specific Supplement for the Patient Experience with Treatment and Self- Management (PETS) Survey
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate how treatment and self-care after kidney transplant impacts people’s lives, relationships, and finances.
.